Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12246356 | 1.00 | LMNA (0.33) | LMNASMN1; SMN2CYP2D6TAAR1MAPT | |
| SCHEMBL20535372 | 0.80 | LMNA (0.39) | LMNASMN1; SMN2MAPTKDM1ACYP1A2 | |
| SCHEMBL23294759 | 0.80 | LMNA (0.39) | LMNASMN1; SMN2MAPTKDM1ACYP1A2 | |
| SCHEMBL20535369 | 0.80 | LMNA (0.39) | LMNASMN1; SMN2MAPTKDM1ACYP1A2 | |
| SCHEMBL837844 | 0.79 | LMNA (0.41) | LMNASMN1; SMN2CYP2D6TAAR1MAPT | |
| SCHEMBL10263865 | 0.79 | LMNA (0.41) | LMNASMN1; SMN2CYP2D6TAAR1MAPT | |
| SCHEMBL834045 | 0.77 | IDO1 (0.40) | LMNASMN1; SMN2CYP2D6TAAR1MAPT | |
| SCHEMBL10264233 | 0.77 | IDO1 (0.40) | LMNASMN1; SMN2CYP2D6TAAR1MAPT | |
| SCHEMBL21729219 | 0.75 | IDO1 (0.47) | LMNASMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23316910 | 0.75 | KDM4E (0.46) | LMNASMN1; SMN2MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | LMNA 1600/4885SMN1; SMN2 740/4885CYP2D6 519/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | LMNA 1864/4885SMN1; SMN2 782/4885CYP2D6 886/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | LMNA 1625/4885SMN1; SMN2 761/4885CYP2D6 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.